– The association between high TLE3 expression and a favorable response to taxane-containing chemotherapy regimens was validated in patients with non-serous ovarian cancer. That TLE3 expression may serve as a marker of chemosensitivity in taxane-treated patients with non-serous histologies. Transducin-like enhancer of Split3 (TLE3) serves as a transcriptional corepressor during cell differentiation and shows multiple roles in different kinds of cancers. TLE3 repressed CRC proliferation partly through inhibition of MAPK and AKT signaling pathways, suggesting the possibility of TLE3 as a biomarker for CRC prognosis.